AHA prez: Upside to Congressional can-kicking is ‘more time to tell the hospital story and educate lawmakers’

As Congress negotiates reimbursement rates, Rick Pollack, president and CEO of the American Hospital Association (AHA), is urging lawmakers to halt any further payment cuts that could compromise patient care and hospital services nationwide. 

“Last week Congress again voted to push back its deadline for funding the federal government for fiscal year 2024 by adopting another continuing resolution that extends current funding levels through the beginning of March,” wrote Pollack in a blog post. “As we have been sharing with you through our various communications channels, a number of important issues affecting hospitals and health systems are being considered as part of this package. These include preserving the moratorium on Medicaid disproportionate share hospital cuts and staving off harmful so-called site-neutral payment policies that don’t account for the differences in the care hospitals provide 24/7.”

Pollack cited recent data showing that for Medicare alone, hospitals were reimbursed at a rate of only 82 cents for every dollar spent in 2022, resulting in approximately $100 billion in underpayments. This is compounded by rising costs and ongoing cybersecurity threats.

AHA was slated to host a “special advocacy update” virtual session with members on January 31.

"The upside to Congress’ repeatedly kicking the can down the road is we now have several more weeks to keep telling the hospital story and educating lawmakers," said Pollack.

Pollack’s full remarks can be read at the link below.
 

Evan Godt
Evan Godt, Writer

Evan joined TriMed in 2011, writing primarily for Health Imaging. Prior to diving into medical journalism, Evan worked for the Nine Network of Public Media in St. Louis. He also has worked in public relations and education. Evan studied journalism at the University of Missouri, with an emphasis on broadcast media.

Around the web

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met. 

When regulating AI-equipped medical devices, the FDA might take a page from the Department of Transportation’s playbook for overseeing AI-equipped vehicles. These run the gamut from assisting human drivers to fully taking the wheel. 

Kit Crancer, RBMA board member, speaks with Radiology Business about key legislative developments on the Hill that will affect the specialty.